


Claims


1. A compound of Formula I:




or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein,

Y is hydrogen or (C₁-C₃)alkyl;

R¹ is (C₁-C₆)alkyl;



R² is phenyl or pyridine substituted with cyano;




optionally substituted with one or two (C₁-C₆)alkyl groups;

R³ is -C(=O)R⁴; and

R⁴ is (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₃-C₈)heterocycloalkyl, (C₃-C₈)cycloalkyl(C₁-C₆)alkyl, (C₃-C₈)heterocycloalkyl(C₁-C₆)alkyl, or heteroaryl, optionally substituted with one, two, three, or four substituents independently selected from the group consisting of halo, (C₁-C₄)alkyl, hydroxyl and (C₁-C₄)alkoxy; .


2. The compound of claim 1, wherein R¹ is methyl, a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof.


3. The compound of claim 1-2, wherein Y is hydrogen or methyl, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof.




4. The compound of claim 1-3, wherein X is pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof:


5. The compound of claim 1-4, wherein W is selected from the group consisting of





or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof.

6. The compound of claim 1-5, wherein W is  or

, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof

7. A pharmaceutical composition comprising a compound, a pharmaceutically acceptable salt, pharmaceutically acceptable solvate or a pharmaceutically acceptable

salt thereof according to any one of claims 1-6, admixed with a pharmaceutically acceptable carrier, excipient or dilutant.

8. A pharmaceutical composition of claim 7 for the treatment of rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, epidermal hyperplasia, cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myolitis, polymyolitis, dermatomyolitis, osteoarthritis, polyarteritis nodosa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, psoriatic epidermal hyperplasia, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, an immune disorder associated with or arising from activity of pathogenic lymphocytes, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, noninfectious uveitis, Behcet's disease or Vogt-Koyanagi-Harada syndrome.

9. The compound of claim 1 selected from the group consisting of
3-cyano-N-(3-(1-(cyclopentylcarbonyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)benzamide;

3-cyano-N-(1-methyl-3-(1-(3-methylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzamide;

3-cyano-N-(3-(1-((2S,3S)-2-hydroxy-3-methylpentanoyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)benzamide;

3-cyano-N-(3-(1-((2S)-2-hydroxy-4-methylpentanoyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)benzamide;

3-cyano-N-(3-(1-[(cis-4-hydroxycyclohexyl)carbonyl]piperidin-4-yl)-1-methyl-1H-indol-5-yl)benzamide;

4-cyano-N-(3-(1-(cyclopentylcarbonyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-(3-[1-(cyclohexylcarbonyl)piperidin-4-yl]-1-methyl-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-(3-(1-[(3,3-difluorocyclopentyl)carbonyl]piperidin-4-yl)-1-methyl-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-(3-(1-[(3,3-difluorocyclobutyl)carbonyl]piperidin-4-yl)-1-methyl-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-(1-methyl-3-(1-[(5-methylisoxazol-3-yl)carbonyl]piperidin-4-yl)-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-(1-methyl-3-(1-[(1-methyl-1H-pyrazol-5-yl)carbonyl]piperidin-4-yl)-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-(1-methyl-3-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-[3-(1-[(1S*,2R*)-2-hydroxycyclopentyl]carbonyl]piperidin-4-yl)-1-methyl-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-(1-methyl-3-(1-[(4-methyl-1,3-oxazol-5-yl)carbonyl]piperidin-4-yl)-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-(1-methyl-3-[1-(tetrahydro-2H-pyran-3-ylcarbonyl)piperidin-4-yl]-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-(1-methyl-3-(1-[(5-methyl-1,3-oxazol-4-yl)carbonyl]piperidin-4-yl)-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-{1-methyl-3-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-{1-methyl-3-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-{1-methyl-3-[1-(pyrimidin-4-ylcarbonyl)piperidin-4-yl]-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-(3-{1-[(6-hydroxypyridin-2-yl)carbonyl]piperidin-4-yl}-1-methyl-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-{3-[1-(3-hydroxy-2,2-dimethylpropanoyl)piperidin-4-yl]-1-methyl-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-{1-methyl-3-[1-(3,3,3-trifluoro-2-hydroxypropanoyl)piperidin-4-yl]-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-{1-methyl-3-[1-(pyrimidin-2-ylcarbonyl)piperidin-4-yl]-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-{1-methyl-3-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-{1-methyl-3-[1-(pyrazin-2-ylcarbonyl)piperidin-4-yl]-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-(3-{1-[(trans-4-hydroxycyclohexyl)carbonyl]piperidin-4-yl}-1-methyl-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-{3-[1-(2-hydroxy-3-methylbutanoyl)piperidin-4-yl]-1-methyl-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-(3-{1-[(cis-4-hydroxycyclohexyl)carbonyl]piperidin-4-yl}-1-methyl-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-{1-methyl-3-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]-1H-indol-5-yl}pyridine-2-carboxamide;

N-{3-[1-(bicyclo[1.1.1]pent-1-ylcarbonyl)piperidin-4-yl]-1-methyl-1H-indol-5-yl}-4-cyanopyridine-2-carboxamide;

4-cyano-N-(3-{1-[(2,2-difluorocyclopropyl)carbonyl]piperidin-4-yl}-1-methyl-1H-indol-5-yl)pyridine-2-carboxamide;

4-cyano-N-{3-[1-(cyclopropylacetyl)piperidin-4-yl]-1-methyl-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-{3-[1-(methoxyacetyl)piperidin-4-yl]-1-methyl-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-{1-methyl-3-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]-1H-indol-5-yl}pyridine-2-carboxamide;

4-cyano-N-(3-(1-(cyclopentanecarbonyl)piperidin-4-yl)-1-ethyl-1H-indol-5-yl)picolinamide;

3-cyano-N-(3-(1-(cyclopentanecarbonyl)piperidin-4-yl)-1,4-dimethyl-1H-indol-5-yl)benzamide;

(R)-3-cyano-N-(1,4-dimethyl-3-(1-(4,4,4-trifluoro-3-hydroxybutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzamide; and

(R)-3-cyano-N-(1-methyl-3-(1-(4,4,4-trifluoro-3-hydroxybutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzamide; or a pharmaceutically acceptable salt, or pharmaceutically acceptable solvate thereof.